ASND — Ascendis Pharma A/S

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1612042 · Denmark
Last close
$271.19
Market Cap
$17.84B
52W High
$282.15
52W Low
$188.08
ADV30
713,003
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 369,657,000 341,346,000 124,576,000 73,973,000 2,427,184,000 964,364,000 926,733,000
Jun 2026 339,285,000 311,627,000 220,465,000 206,970,000 2,286,020,000 812,260,000 849,529,000
Mar 2026 246,601,000 229,086,000 24,812,000 629,339,000 2,003,279,000 572,820,000 1,515,306,000
Dec 2025 247,500,000 223,902,000 6,442,000 -33,562,000 1,302,570,000 616,041,000 1,465,391,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$349,512,000
Investing CF
$-13,051,000
Financing CF
$-35,581,000
CapEx
$-8,485,000
Dividends Paid
—
Buybacks
$-103,412,000
EPS Diluted TTM
$11.03
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,878,483,000
Inventory
$310,576,000
Receivables
$224,102,000
ST Investments
—
EBIT TTM
$219,526,000
Pretax Income TTM
$97,839,000
Interest Exp TTM
$121,687,000
Analysts
21

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,047,020,032
EBITDA
$263,454,000
Free Cash Flow
$12,771,750
Enterprise Value
$16,943,709,184
Total Cash
$812,259,968
Total Debt
$450,073,984
Shares Out
65,783,370
Trailing EPS
$13.02
Book Value
$25.38
ROE
118.8%
ROA
9.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 720,132,000 -136,271,000 -228,034,000 1,302,570,000 1,465,391,000 -162,821,000 53,897,000
Dec 2024 363,641,000 -278,763,000 -378,084,000 1,179,495,000 1,285,201,000 -105,706,000 -306,197,000
Dec 2023 266,718,000 -455,541,000 -481,447,000 825,587,000 971,284,000 -145,697,000 -467,361,000
Dec 2022 51,174,000 -561,814,000 -583,194,000 1,089,738,000 826,390,000 263,348,000 -495,699,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.22

Max Pain — expiry 2026-12-18

max pain strike: $240.00 · spot: $270.33 · call oi: 2,246 · put oi: 1,158

Peers — same industry

TickerNameMarket CapLastDaily %
JAZZ Jazz Pharmaceuticals plc $15.45B $240.71 —
ALNY ALNYLAM PHARMACEUTICALS, INC. $20.96B $156.50 —
BBIO BridgeBio Pharma, Inc. $14.96B $76.80 —
VTRS Viatris Inc $23.45B $20.45 —
ELAN Elanco Animal Health Inc $12.92B $25.85 —

News headlines (Yahoo Finance, 1h cache)

Ascendis Pharma (ASND) Could Be 12% Below Fair Value Following Q3 Earnings
2026-11-13 12:12 · Yahoo
Ascendis Pharma (ASND) Stock Looks About Right After An 18% Rise
2026-11-13 11:10 · Yahoo
Ascendis Pharma earnings analysis: questions answered and next catalysts
2026-11-12 20:55 · Yahoo
Ascendis Pharma A/S Q3 Earnings Call Highlights
2026-11-12 17:15 · Yahoo
Ascendis (ASND) Q3 2026 Earnings Call Transcript
2026-11-12 15:29 · Yahoo
Ascendis Pharma Reports Third Quarter 2026 Financial Results
2026-11-12 12:30 · Yahoo
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
2026-11-10 21:01 · Yahoo
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
2026-11-06 13:00 · Yahoo
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 21:01 · Yahoo
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
2026-10-26 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.